Results 161 to 170 of about 872,419 (247)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Correction: Unmasking the hidden risk: potential implication of pullback pressure gradient in ischemia-negative lesions. [PDF]

Cardiovasc Interv Ther
Ando H, Collet C, Sakai K, Ohashi H, Amano T.   +4 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

The Role of Academic Medical Centers in Personalized Experimental Therapeutic Development: Key Considerations. [PDF]

Neurology
Dies KA, Yu TW, Chamberlin NL, Holm IA, Beggs AH, Kennedy KO, Fleming JC, Pomeroy SL, Urion DK, Srivastava S.   +9 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Journal of Population and Therapeutics and Clinical Pharmacology

Asma Arshad, Sumera Zaib
openalex   +3 more sources

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. [PDF]

Diabetes Care
Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Christofides EA, DeFronzo RA, Eilerman B, Findling JW, Fonseca V, Hamidi O, Handelsman Y, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LL, Umpierrez G, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators* .   +26 more
europepmc   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment. [PDF]

Diabetes Care
DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Buse JB, Christofides EA, Eilerman B, Findling JW, Handelsman Y, Kahn SE, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LA, Umpierrez G, Shambharkar S, Tudor IC, Schlafly TK, Einhorn D, CATALYST Investigators* .   +26 more
europepmc   +1 more source